DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: Phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues

This publication has 42 references indexed in Scilit:

• Evidence for Lipoxygenase-Catalyzed Bioactivation of Phenytoin to a Teratogenic Reactive Intermediate: In Vitro Studies Using Linoleic Acid-Dependent Soybean Lipoxygenase, and in Vivo Studies Using Pregnant CD-1 Mice
  Toxicology and Applied Pharmacology, 1995
• Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy
  JAMA, 1994
• Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome
  New England Journal of Medicine, 1990
• Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: A unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds
  Toxicology and Applied Pharmacology, 1989
• Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and α-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetase
  Toxicology and Applied Pharmacology, 1989
• GENETIC PREDISPOSITION TO PHENYTOIN-INDUCED BIRTH DEFECTS
  The Lancet, 1985
• Teratogenicity of diphenylhydantoin in the New Zealand white rabbit
  Teratology, 1980
• The fetal hydantoin syndrome
  The Journal of Pediatrics, 1975
• The Teratogenic Risk of Antiepileptic Drugs
  Epilepsia, 1975
• Comparative embryotoxicity of diphenylhydantoin and some of its metabolites in mice
  Teratology, 1974